1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6FF8B8ABDEEF241C2002589AA002C7020
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-case-study-how-horizon-therapeutics-created-ophthalmic-blockbuster-rare-disease-autoimmune-area-thyroid-eye-disease?opendocument
18
19opendocument
2034.228.52.21
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease

ID: 5760


Features:

44 Info Graphics

13 Data Graphics

230+ Metrics

9 Narratives


Pages/Slides: 70


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease”

STUDY OVERVIEW

In January 2020, Horizon Therapeutics made history with the FDA approval of Tepezza (teprotumumab-trbw), the first IGF-1R blocker for patients with thyroid eye disease (TED). While its closest competitors, Immunovant and Novartis, continue to await Phase 3 trial completions until Q1 2025, Tepezza's first-mover advantage propelled it to surpass the remarkable milestone of $1 billion in just 18 months since its launch.


Best Practices, LLC presents a detailed case study that explores the winning strategies and approaches that have propelled this ophthalmic blockbuster in the rare disease autoimmune area of thyroid eye disease. This in-depth analysis highlights the education campaigns, patient support initiatives, innovative partnerships, and competitive resourcing implemented by Horizon Therapeutics to provide valuable lessons for industry stakeholders. Launch leaders will gain actionable insights from our comprehensive case study to shape their own success stories.

KEY TOPICS

  • Introduction to Horizon Therapeutics And Tepezza For TED
  • Tepezza’s Progression Since Launch
  • Disease Awareness, Patient Education, and Symptom Identification
  • Patient Access & Support Help TED Patients Navigate Authorization, et. al.
  • D2C Education & Communications: A Cornerstone Of Tepezza’s Education Campaign
  • Roadblocks And Resolutions In Tepezza’s Journey
  • Partnerships: Tepezza Leveraged Strengths Of Partners To Enter Market
  • Financial Health Of Horizon Since The Release Of Tepezza
  • Tepezza Staffing Analysis: Examining the Talent to Compete in the TED Market
  • Summary Lessons Learned From Tepezza’s Successful Market Entry

KEY METRICS

  • Tepezza’s efficacy
  • Tepezza’s unit cost per dose analysis
  • Blockbuster sales curve
  • Average number of Tepezza sales representatives and average number of targeted physicians
  • Horizon Therapeutics’ operating margin, return on research capital, and net income margin compared to industry averages
  • Horizon Therapeutics’ quick ratio, debt ratio, and return on equity compared to industry averages
  • Average number of sales FTEs, MSLs, Patient Access Liaisons in the US market
  • FTE ratio for Tepezza
  • Geographic distribution of Tepezza FTEs

SAMPLE KEY FINDINGS

  • Blockbuster Sales Curve: Tepezza's sales growth shows the rapid uptake of a blockbuster passing the $1 billion milestone 18 months post launch.
  • Patient Support Program: Horizon has introduced Patient Access Liaisons who team up with patients and their HCPs to support them throughout the treatment process, including providing assistance with payers.

METHODOLOGY

Best Practices, LLC conducted extensive secondary research to examine how Horizon Therapeutics created an ophthalmic blockbuster in a rare disease autoimmune area.

Industries Profiled:
Biotech; Pharmaceutical


Companies Profiled:
Amgen; Horizon Therapeutics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.